Vaderis TherapeuticsFactsSource Subscribe

Late additionFunding round

Funding round for Vaderis Therapeutics led by Life Sciences at Goldman Sachs Alternatives, TCGX

Biotechnology, rare vascular diseases · Basel, Switzerland

$152mRound size according to the source

SourcingClub was not involved in this transaction.

Vaderis Therapeutics closes a $152m Series B financing jointly led by Goldman Sachs Alternatives and TCGX. EQT Life Sciences participates with $17.5m, and the funds finance the global Phase 3 study of engasertib.

In context

In August 2026 it is the 2nd of 4 deals in Healthcare on the Deal-Radar.

Deal-Radar editorial team · responsible:

late addition, source dated 11 Aug 2026: eqtgroup.com

Who was involved.

Lead investor
Life Sciences at Goldman Sachs Alternatives, TCGX
Target
Vaderis Therapeutics, Basel
Type
Funding round
Country
Switzerland
Source dated
11/08/2026
Round size
$152m, according to the source

Deal-Radar no. 47-162 · added in Week 47/2026, first reported on 11/08/2026 · publicly reported, no guarantee · SourcingClub was not involved in this transaction. Report an error · Sources and limits

We report publicly announced information and link the source; we accept no liability for its accuracy. No offer and no investment, legal or tax advice. The operators of linked pages are responsible for their content. We correct errors as soon as we learn of them. The context is based only on deals recorded in the Deal-Radar and is not complete.

August 2026 on the Deal-Radar.

2 of 33 deals were of the type Funding round.

  1. Strategic11
  2. Add-on6
  3. Buy-out4
  4. Carve-out3
  5. Succession3
  6. Secondary3
  7. Funding round2
  8. Insolvency1

New deals every day. By email on Mondays.

All deals of the previous week in one email, with source and adviser.

Weekly email every Monday, in German.

Information from public sources, without guarantee and without claim to completeness. No investment or legal advice. Published on 21 November 2026.